Pharmaceutical companies Actavis plc and Forest Laboratories, Inc. have agreed to sell or relinquish their rights to four generic pharmaceuticals that treat hypertension, angina, cirrhosis, and prevent seizures to settle Federal Trade Commission charges that Actavis’s acquisition of Forest likely would be anticompetitive. According to the FTC’s complaint, Actavis’s acquisition of Forest, as originally proposed, […]
Monthly Archives: June 2014
L’Oréal Settles FTC Charges Alleging Deceptive Advertising for Anti-Aging Cosmetics
Cosmetics company L’Oréal USA, Inc. has agreed to settle Federal Trade Commission charges of deceptive advertising about its Lancôme Génifique and L’Oréal Paris Youth Code skincare products. According to the FTC’s complaint, L’Oréal made false and unsubstantiated claims that its Génifique and Youth Code products provided anti-aging benefits by targeting users’ genes. “It would be […]
FTC Continues Crack Down on Deceptive Debt Collection; Houston-based Defendants Agree to Stop Deceptive Fees and Practices
A Houston debt collection company, RTB Enterprises, Inc., which does business as Allied Data Corporation, and Raymond T. Blair, its president and sole shareholder, have agreed to a federal court order prohibiting them from the allegedly deceptive tactics they have been using to bully English and Spanish-speaking consumers into paying debts and unnecessary fees. According […]
FTC Approves Final Orders Settling Charges of U.S.-EU Safe Harbor Violations Against 14 Companies
After a public comment period, the Federal Trade Commission has approved final orders that settle charges against 14 companies for falsely claiming to participate in the international privacy framework known as the U.S.-EU Safe Harbor. Three of the companies were also charged with similar violations related to the U.S.-Swiss Safe Harbor. The FTC previously announced […]
Proposed Regulatory Capital Reporting Changes
FIL-32-2014 June 25, 2014 Proposed Regulatory Capital Reporting Changes Summary: The federal banking agencies are requesting comments on proposed revisions to the risk-weighted assets portion of Schedule RC-R, Regulatory Capital, of the Consolidated Reports of Condition and Income (Call Report). These proposed reporting changes would incorporate into Part II of Schedule RC-R the standardized […]
FTC Approves Final Consent Settling Charges that Home Security Company ADT’s Endorsements Deceived Consumers
Following a public comment period, the Federal Trade Commission has approved a final consent order settling charges that the home security company ADT LLC misrepresented that paid endorsements from safety and technology experts who appeared as guests on news programs and talk shows were independent reviews. First announced in March 2014, the settlement prohibits ADT […]
Defendants Who Allegedly Took Millions from Consumers Trying to Launch Or Succeed in Home-Based Businesses Settle FTC Charges
The Federal Trade Commission halted the allegedly deceptive practices of two schemes that targeted consumers hoping to succeed through home-based businesses. The defendants behind both operations have agreed to settlements that will prohibit future misconduct, and in the Tax Club case, they will surrender assets valued at more than $15 million. The FTC cases against […]
FTC Stops Scammers Who Targeted Spanish-speaking Consumers and Sent Unwanted or Defective Products and Then Refused to Return Consumers’ Money
At the Federal Trade Commission’s request, a federal judge has temporarily halted and frozen the assets of an operation that swindled Spanish-speaking consumers across the country by routinely sending unordered or defective products, including a phony weight-loss belt, and then making it difficult, impossible, or costly for consumers to obtain relief. The FTC seeks to […]
FTC Approves Final Order Settling Charges That Akorn Enterprises’ Acquisition of Hi-Tech Pharmacal Was Anticompetitive
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Akorn Enterprises’ $640 million acquisition of Hi-Tech Pharmacal, Inc. was anticompetitive and would lead to higher prices for consumers in several current and future generic drug markets. According to the FTC’s complaint, originally announced in April 2014, the […]
FTC Amicus Brief: Improper Use of Restricted Drug Distribution Programs May Impede Generic Competition
The Federal Trade Commission has filed an amicus brief in the U.S. District Court for the District of New Jersey explaining that a brand name drug manufacturer’s improper use of a restricted drug distribution program to impede generic competition could violate the antitrust laws. The FTC filed the brief in the matter of Mylan Pharms., […]